Acquisition of multidrug resistance by L1210 leukemia cells decreases their tumorigenicity and enhances their susceptibility to the host immune response

Cancer Immunology, Immunotherapy

Volumn 54, Issue 4, 2005, Pages 328-336

  Martín Orozco, Elena ^a,b   Ferragut, José Antonio ^a   Garcia Peñarrubia, Pilar ^b   Ferrer Montiel, Antonio ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Apoptosis; Cell surface molecules; Fas molecule; MDR; MHC class I; Tumour immunity

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HOST SUSCEPTIBILITY; IMMUNE RESPONSE; IMPLANTATION; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; SURFACE PROPERTY; UPREGULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGEN PRESENTATION; ANTIGENS, CD95; CELL PROLIFERATION; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GAMMA RAYS; LEUKEMIA L1210; MICE; MICE, INBRED DBA; RECEPTORS, INTERFERON; SURVIVAL RATE;

EID: 13744253365     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0588-7     Document Type: Article

References (33)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361
2. Azuma E, Masuda S, Qi J, Kumamoto T, Hirayama M, Nagai M, Hiratake S, Umemoto M, Komada Y, Sakurai M (1997) Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias. Eur J Haematol 59(1):14
3. Bellamy WT (1996) P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 36:161
4. Bradley M, Zeytun A, Rafi-Janajreh A, Nagarkatti PS, Nagarkatti M (1998) Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood 92(11):4248
5. Cao X, Chen G, He L, Zhan W, Yu Y, Wang J (1997) Involvement of MHC class I molecule and ICAM-I in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene. J Cancer Res Clin Oncol 123:602
6. Castro-Galache MD, Ferragut JA, Barbera VM, Martin-Orozco E, Gonzalez-Ros JM, Garcia-Morales P, Saceda M (2003) Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int J Cancer 104(5):579
7. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut JA, Olive D (2000) Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 60:4403
8. Cullen K, Davey R, Davey M (2001) The drug resistance proteins, multidrug resistance-associated protein and P-glycoprotein, do not confer resistance to Fas-induced cell death. Cytometry 43(3):189
9. Cullen KV, Davey RA, Davey MW (2001) Drug resistance does not correlate with resistance to Fas-mediated apoptosis. Leuk Res 25(1):69
10. Fichtner I, Stein U, Hoffmann J, Winterfeld G, Pfeil D, Hentschel M (1994) Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance and proliferation markers, immunogenicity. Anticancer Res 14(5A):1995
11. Fuji H, Murakami MJ (1983) Differential tumour immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines, III: control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes. J Natl Cancer Inst 70(1):119
12. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615
13. Izquierdo MA, Neefjes JJ, Mathari AE, Flens MJ, Scheffer GL, Scheper RJ (1996) Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br J Cancer 74(12):1961
14. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153
15. Labroille G, Dumain P, Lacombe F, Belloc F (2000) Flow cytometric evaluation of fas expression in relation to response and resistance to anthracyclines in leukemic cells. Cytometry 39(3):195
16. Landowski TH, Gleason-Guzman MC, Dalton WS (1997) Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 89(6):1854
17. Laurent G, Jaffrézou JP (2001) Signaling pathways activated by daunorubicin. Blood 98:913
18. Ogasawara J, Watanabe-Fukunage R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806
19. Puddu P, Fais S, Luciani F, Gherardi G, Dupuis ML, Romagnoli G, Ramoni C, Cianfriglia S, Gessani S (1999) Interferon-gamma up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. Lab Invest 79(10):1299
20. Qin Z, Blankesistein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNg receptor expression by nonhematopoietic cells. Immunity 12:677
21. Rapp L, Fuji H (1983) Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumours as defined by syngeneic monoclonal antibodies. Cancer Res 43(6):2592
22. Roninson IB (1992) The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43:95
23. Scheper RJ, Dalton WS, Grogan TM, Schlosser A, Bellamy WT, Taylor CW, Scuderi P, Spier C (1991) Altered expression of P-glycoprotein and cellular adhesion molecules on human multidrug-resistant tumor cells does not affect their susceptibility to NK-and LAK-mediated cytotoxicity. Int J Cancer 48(4):562
24. Seliger B, Harders C, Wollscheid U, Staege MS, Reske-Kunz AB, Huber C (1996) Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol 24(11):1275
25. Shtil AA, Turner JG, Durfee J, Dalton WS, Hua Y (1999) Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 93(6):1831
26. Smyth MJ, Krasovkis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumour cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A 95(12):7024
27. Soto F, Canaves JM, Gonzalez-Ros JM, Ferragut JA (1992) Rapid kinetics of the interaction between daunomycin and drug-sensitive or drug-resistant P388 leukemia cells. FEBS Lett 301:119
28. Soto F, Planells-Cases R, Canaves JM, Ferrer-Montiel AV, Aleu J, Gamarro F, Castanys S, Gonzalez-Ros JM, Ferragut JA (1993) Possible coexistence of two independent mechanisms contributing to anthracycline resistance in leukemia P388 cells. Eur J Cancer 29A(15):2144
29. VandenDriessche T, Bakkus M, Toussaint-Demylle D, Thielemans K, Verschueren H, De Baetselier P (1994) Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens. Clin Exp Metastasis 12(1):73
30. Wang YY, Zheng XX (2002) A flow cytometry-based assay for quantitative analysis of cellular proliferation and cytotoxicity in vitro. J Immunol Methods 268:179
31. Weisburg JH, Curcio M, Caron PC, Raghu G, Mechetner EB, Roepe PD, Scheinberg DA (1996) The multidrug resistance phenotype confers immunological resistance. J Exp Med 183(6):2699
32. Woods G, Lund LA, Naik M, Ling V, Ochi A (1988) Resistance of multidrug-resistant lines to natural killer-like cell-mediated cytotoxicity. FASEB J 2(12):2791
33. Zhihai Q, Blankestein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 12:677